Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR+
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Nov 08, 2023 5:00pm EST

XORTX Announces Share Consolidation

Nov 02, 2023 7:00am EDT

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023

Oct 27, 2023 5:30pm EDT

XORTX Announces Results of Special Meeting of Shareholders

Oct 25, 2023 5:00pm EDT

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

Oct 25, 2023 7:00am EDT

XORTX Announces Rescheduling of Special Meeting of Shareholders

Oct 12, 2023 7:00am EDT

XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution

Oct 04, 2023 7:00am EDT

XORTX Calls Special Meeting of Shareholders

Sep 28, 2023 7:00am EDT

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023

Sep 11, 2023 7:00am EDT

XORTX Announces Participation at Upcoming Investor Conferences

Sep 07, 2023 7:00am EDT

XORTX Joins the Kidney Foundation and Kidney March

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …18
  • arrow_forward
rss_feed News RSS
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap